Cara Therapeutics Inc (CARA)

Shares of Cara Therapeutics Inc (CARA) dropped by 48.85% from $1.23 to $0.6291 in the trading on Monday, December 18, 2023. The reason why CARA down today is due to the outcome from Part A of the KIND 1 study, where oral difelikefalin, as an adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adults with atopic dermatitis (AD), did not show a meaningful clinical benefit compared to TCS alone. As a result, Cara Therapeutics has decided to discontinue its clinical program in pruritus associated with atopic dermatitis.